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EVALUATION OF CLINICAL AND PATHOLOGICAL 
RESPONSE AFTER TWO CYCLES OF NEOADJUVANT 
CHEMOTHERAPY ON SUDANESE PATIENTS WITH 
LOCALLY ADVANCED BREAST CANCER  




BACKGROUND: The use of neoadjuvant chemotherapy in treating breast cancer has shown efficacy 
in downstaging primary tumors, and allows breast conservative surgery to be performed instead of 
mastectomy. This study aims to evaluate patterns of clinical and pathological response after two cycles 
of neoadjuvant chemotherapy in patients with locally advanced breast cancer. 
MATERIALS AND METHODS:  This is a prospective study. Ninety-eight patients who presented from 
April 2009 through May 2011 with locally advanced breast cancer and treated with neoadjuvant 
chemotherapy were included. 
RESULTS:  The clinical response rate was 83%; 11 patients (11.2%) had a complete clinical remission 
(cCR); 71 had a partial remission (72.4%); 13 had stable disease (13.3%), and 3 had progressive 
disease (3.1%). Seven patients had complete pathological response.  
CONCLUSION: Neoadjuvant chemotherapy can achieve a high objective response rate in patients 
with locally advanced breast cancer even after two cycles. We recommend further research to find 
predictors for response. 






The value of adjuvant chemotherapy in treating 
breast cancer is well documented. The idea of 
neoadjuvant chemotherapy has been recently 
applied to breast cancer treatment and studies 
have shown the efficacy of neoadjuvant 
chemotherapy in down-staging the primary tumor 
(1). The use of neoadjuvant chemotherapy thus 
allows breast conservation surgery to be 
performed instead of mastectomy. The Milan 
Group, using a combination of doxorubicin and 
vincristine, achieved an 80% response rate with 
15% of patients attaining complete clinical 
response (2). Tumor shrinkage by the 
neoadjuvant chemotherapy can be easily 
monitored clinically both by physicians and 
patients. For physicians, continuation of 
treatment is reasonably determined based on 
efficacy. For patients, compliance with the 
scheduled courses of chemotherapy is increased 
because they, themselves, experience the 
efficacy, which helps them mentally to overcome 
the unpleasant adverse effects (3). The 
pathological response to the neoadjuvant 
chemotherapy provides reliable prognostic 
information (4). 
     While locally advanced breast cancer (LABC)  
is an unusual presentation among women in the 
western world, in Sudan, this stage is not only 
common but it also affects women at a younger 
age (5).  
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This study evaluates the patterns of response to 
neoadjuvant chemotherapy and its impact on type 
of surgery in patients with locally advanced 
breast cancer. 
 
MATERIALS AND METHODS 
 
A total of ninety-eight patients who presented in 
April 2009 through May 2011 with locally 
advanced breast cancer (LABC) were treated with 
neoadjuvant chemotherapy in the combined 
breast clinic in National Cancer Institute. In the 
TNM staging classification, LABC is represented 
by stage IIIA (T0-N2; T1/2 - N2; T3 - N1/2), 
stage IIIB (T4, N0-2) and stage IIIC disease (any 
T, N3). 
Various chemotherapy schedules were used 
according to standard practice at different times. 
For much of this period, the standard neoadjuvant 
treatment regimen was 5-fluorouracil, epirubicin 
and cyclophosphamide (FEC) with two schedules 
used: 500 mg/m
2
 5-fluorouracil, 75 mg/m
2
 
epirubicin and 500 mg/m
2
 cyclophosphamide or 
600 mg/m
2
 5-fluorouracil, 60 mg/m
2
  epirubicin 
and 600 mg/m
2
 cyclophosphamide, both for 6 
cycles on a 21-day cycle. Forty three patients 
were treated with the FEC schedule. Other 
chemotherapy schedules used included single 
agent docetaxel (100 mg/m
2
 q21 for four cycles, 





 q21 for four 
cycles,15 patients), CMF (oral cyclophosphamide 
100 mg/m
2
 day 1–14 and intravenous 
methotrexate 40 mg/m
2
 and 5-fluorouracil 600 
mg/m
2
 days 1 and 8, q28 for six cycles, five 





 days 1 and 22, mitomycin 
C7 mg/m
2
 day 1, q42 for 3 cycles, six patients), 
MM (methotrexate 30 mg/m
2
 and mitoxantrone 7 
mg/m
2
, q21 for six cycles, seven patients). 
Baseline patient and tumor characteristics 
recorded included age, tumor stage, nodal stage, 
tumor grade, estrogen receptor (ER) status and 
progesterone receptor (PR) status. Clinical 
response was assessed after two cycles of 
chemotherapy (at the 6th week from baseline 
measurements) and at the end of the treatment. 
Union for International Cancer control (UICC) 
criteria was used in recording response. A 
complete clinical response (cCR) was achieved 
when the original mass became impalpable. A 
partial response (cPR) represented a 50% or 
greater reduction in bi-dimensional tumor 
measurements. 
Progressive disease (cPD) was recorded if 
bi-dimensional measurements increased by 20% 
or more. All others were classified as stable 
disease (cSD). Pathological response was 
assessed at definitive surgery on completion of 
neoadjuvant chemotherapy. A pathological 
complete response (pCR) was noted when there 
was no evidence of residual tumor on histological 
examination of the surgical specimen. Patients 
with residual ductal carcinoma in-situ (DCIS) 
and no evidence of residual invasive disease were 
included in this category. The pCR rate was 
compared by response category after two cycles 
of chemotherapy. The rates of mastectomy and 
breast-conserving surgery were noted for all 
patients undergoing operation and these rates 
were compared by response categories. All 
summary statistics were stated with 95% 
confidence limits. An appropriate method for 
small samples was applied to the percentages and 
odds ratios were derived using logistic regression 
methods (SPSS version 17).  
The consent of the patients was obtained. A 
full explanation of the purposes and nature of the 
study was conveyed to them. The potential 
participants were clearly assured that their 
participation in this study was voluntary and that 
they could withdraw at any stage and that any 
data obtained would be treated confidentially and 





Ninety-eight patients receiving primary 
chemotherapy for locally advanced breast cancer 
were studied. The median age of the patients at 
the time of diagnosis was 46 years (range: 25–
71). About 43.9% of the patients (n=43) were 
living in rural areas while 56.1% (n=55) came 
from urban areas. In terms of menopausal status, 
61 (62.2%) patients were pre-menopausal while 
37 (37.8%) were post-menopausal. The mean 
tumor diameter measured clinically before 
neoadjuvant chemotherapy was 9.6 cm (range 4–
18 cm). Axillary nodal status was N0 in 3 
patients (3.1%), N1 in 22 patients (22.4%), N2 in 
66 patients (67.3%) and N3 in 7 patients (7.1%). 




Thirteen patients (13.3%) had Stage IIIa disease, 
77 patients (78.6%) had Stage IIIb disease and 8 
patients (8.2%) had Stage IIIc disease.  
     A histological classification was made: 76 
patients (77.6%) were classified as invasive 
ductal carcinoma (IDC), 15 as invasive lobular 
carcinoma (ILC) (15.3%) and 7 as other types 
(7.1%), including mixed invasive patterns, figure 
(4). Malignancy grading was also done: 2 (2%) 
were grade I, 20 (20.4%) were grade II and 76 
(77.6%) were grade III. 
Estrogen receptors showed positivity in 66 
patients (67.3%), and progesterone receptors in 
55 patients (56.1%). The mean tumor diameter 
measured in the surgical sample after 
neoadjuvant chemotherapy was 2.6 cm (range 0–
12 cm). Eleven patients (11.2%) had a clinical 
complete remission (cCR), 71 had a partial 
remission (72.4%), 13 had stable disease (13.3%) 
and 3 had progressive disease (3.1%). Clinical 
examination of the axilla revealed a complete 
response in 16 (16.3%) and an incomplete 
response in 50 (51%).  
Following NAC, 33 patients (33.7%) underwent 
breast conservative surgery (BCS), while 49 
(66.3%) had total mastectomy. All patients had 
axillary lymph node dissection (ALND).The 
other 16 patient continued their cycles of 
chemotherapy. Seven patients (7.1%) attained 
complete pathological response (pCR), 17 
(17.3%) demonstrated partial response, while 58 
patients showed pathological stable disease. 
There was no significant difference in the 
response rates based on the stage of the disease 
(p= 0.036).  
Comparison between clinical and pathologic 
response was also made. Based on clinical 
assessment, 6 of the 11 patients (54.5%) who 
were considered as complete clinical responder, 
in fact, had pCR. On the other hand, one patient 
of the 71 (1.4%) patients who were considered as 
partial clinical responders was eventually found 
to have pCR. 
 
Table 1: Baseline patient and tumour characteristics and the distribution of the characteristics by 
clinical response after two cycles of chemotherapy, 2011 (N= 98). 
Table 2 shows univariate analysis for prediction 
of a pCR by response at two cycles and for 
various known prognostic factors, including age, 
baseline tumour stage, nodal status, histological 
grade and ER status. Response at two cycles and 
baseline ER status significantly predict for pCR 
in the univariate model.  
Parameter  Total population        Responders after 
 Two cycles 
Non-responders 
after two cycles  
Age    
   Median 46     47      50 
Tumor stage    
   III a 13 (13.3 %) 13 (15.8 %)  0  
   III b 77 (78.6 %) 67 (81.7 %) 10 (62.5%) 
   III c 8 (8.2 %) 2 (2.5%) 6 (37.5 %) 
Nodal stage    
   N0 3 (3.1%) 3 (3.6%) 0 
   N1 22 (22.4%) 20 (24.4%) 2 (12.5%) 
   N2 66 (67.3%) 58 (70.7%) 8 (50%) 
   N3 7 (7.1%) 1 (1.3 %) 6 (37.5%) 
Tumor grade    
  G1 2 (2%) 2 (2.5%) 0 
  G2 20 (20.4%) 10 (12.2%) 10 (62.5%) 
  G3 76 (77.6%) 70 (85.3%) 6 (37.5%) 
ER status    
  +ve 66 (67.3%) 62(75%) 4 (12.5%) 
   -ve 32 (32.7%) 18 (25%) 14 (87.5%) 






Table 2: Univariate regression analyses for the prediction of a complete pathological response by various 
baseline patient, tumour characteristics and clinical response after two cycles, 2011 (N= 98).
 
Variable            Value Univariate regression model 
Odds ratio               P value  95% CI        
Response after two cycles Response vs. non-response 22.5                     0.003 2.9-171.6     
 Age <50 vs. >50 years 1.2                       0.656 0.5-3.2                     
Histologic grade 1 + 2 vs. 3 0.4                       0.085 0.1-1.0   
ER status Positive vs. negative 0.4                       0.04 0.1-1.0        
 
Table 3: Showing correlation between the histological type of tumors and clinical response, 2011 
   (N= 98). 
 
 Clinical response Total 
complete partial Stable disease progressive disease 
Histological 
type 
Ductal 10 62 4 0 76 
Lobular 1 2 9 3 15 
Medullary 0 5 0 0 5 
Tubular 0 2 0 0 2 




The use of neoadjuvant chemotherapy to treat 
locally advanced breast cancer has been shown 
to be efficacious. In the National Surgical 
Adjuvant Breast and Bowel Project B-18, an 
objective response was seen in 80% of 747 
patients after they received neoadjuvant 
chemotherapy (6). In our study, the overall 
clinical response rate was 83.6%. This high 
percentage permits breast conserving surgery in 
one third of such patients. The short-term effect 
of neoadjuvant chemotherapy on breast cancer is 
positive, and clinical response, even pCR, may 
be attained in some patients (7).  
There still might be residual tumor 
histologically in patients who achieved complete 
clinical response (8-10). In our study, 11 patients 
(12%) completed clinical response, 6 of them 
completed pathological response, and the other 5 
had residual disease histologically. 
Several groups have proposed breast-
sparing radiotherapy for patients who achieved 
complete clinical response (11). Jacquillat et al. 
noted an overall breast recurrence rate of 6.0% 
among 250 patients treated with neoadjuvant 
chemotherapy followed by breast radiotherapy 
(12). Accurate estimation of the tumor size after 
neoadjuvant chemotherapy is crucial for 
deciding the type and extent of operation to be 
performed. 
   Assessing residual disease after the 
administration of chemotherapy is important in 
helping to select patients for breast conservation 
surgery (13). Apart from measuring the tumor 
diameter directly, imaging techniques such as 
mammography and ultrasonography may 
provide further information about the tumor size 
after chemotherapy (14). Whether Magnetic 
Resonance Imaging (MRI) can provide a better 
correlation with the pathological size remains 
uncertain, but early results appear promising. 
Cross et al. have shown that the reduction in 
tumor enhancement on an MRI scan correlates 
with the extent of the disease as seen at the 
pathological examination (7).  
        We have also found that higher grade is 
independently associated with either complete or 
partial clinical response in the breast. Eighty 
eight per cent of patients who developed clinical 
response had poor grade at the time of diagnosis. 
There exist numerous studies that have shown 
better responses in rapidly proliferating tumors 




with a higher grade (Petit et al. 2004; Guarneri et 
al. 2006; Penault et al. 2002) (15-17). 
In concordance with previous studies, we 
have observed a positive correlation with 
estrogen receptors and overall (clinical and 
pathological) response. Surprisingly, a higher 
objective response rate (cCR+ pCR) was seen in 
patients who are ER-positive as compared with 
ER-negative patients (p=0.004), with 94% of 
ER-positive tumors responding, compared to 
only 57% of ER negative tumors. 80% of the 
patients who achieved cCR are ER-positive. All 
the patients who attained pCR are ER-positive. 
This finding seems to contradict the finding from 
Danishad et al. (2006), who identified that ER 
negative tumors respond better for chemotherapy 
(17-18).  
 A varying correlation between clinical 
response and histological type of tumors has 
been reported in previous studies. For example, 
Brifford et al. reported a highly significant 
clinical response in patients with invasive ductal 
carcinoma (IDC)(19). Mathieu et al. and 
Newman et al. reported that invasive lobular 
carcinoma (ILC) is an independent predictor of 
ineligibility for BCS after neoadjuvant 
chemotherapy compared with IDC (20). 
Although all these studies show that ILC patients 
are less likely to achieve BCS after neoadjuvant 
chemotherapy, they do not address whether the 
use of neoadjuvant chemotherapy improves the 
baseline BCS rates for ILC patients (20-21). In 
our study, seventy-two out of 76 patients 
diagnosed as invasive ductal carcinoma achieved 
clinical response (complete or partial) to NAC 
(Table 3). A complete clinical response was seen 
in only one patient with ILC (1%), which is also 
consistent with other ILC series in the literature 
(21). No lobular carcinomas had a complete 
pathological response to NAC in this study. 
These findings suggest that histological type in 
breast carcinoma may play an important role in 
predicting the degree of tissue response and 
pathologic response to NAC. More importantly, 
they raise the question as to whether NAC 
should be used in cases of invasive lobular 
carcinoma.  
In conclusion, there is strong evidence that 
treatment of locally advanced breast cancer with 
neoadjuvant chemotherapy will downgrade the 
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